Figure 1 from Prognostic Modeling Integrating RAS and SMAD4 Status in Patients with BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer

Authors:

Open Access

10 November 2026

other
Published by American Association for Cancer Research (AACR)

DOI:10.1158/2767-9764.34970253

Abstract

Oncoprint of recurrent genomic alterations from the NGS panel with clinicopathologic annotations. Each column represents one patient and each row a recurrently altered gene; cells are binary-coded as mutated (Mut) vs. wild type (WT). Genes are ordered by decreasing cohort prevalence (percentages shown on right), with APC (85%), TP53 (80%), RAS (51%), PIK3CA (19%), SMAD4 (14%), and FBXW7 (12%) among the most frequent; less common events include ERBB2 amplification or mutation, PTEN mutation or loss, EGFR amplification, and FGFR1 fusion. Clinical annotation tracks indicate sex, primary site (left vs. right), resection of the primary tumor, number of metastatic sites (≥2 vs. 1), and onset of metastases (synchronous vs. metachronous). Columns are arranged to highlight shared and the x-axis shows the patient count scale. Alt, altered.